EU welcomes Ukrainian law restoring independence to anti-corruption agencies
A total of 331 out of 340 lawmakers present voted in favor of the bill on Thursday, forming an overwhelming constitutional majority.
Last week, major anti-government protests broke out across Ukraine after the country's parliament approved a bill that brought the two main bodies – the National Anti-Corruption Bureau of Ukraine (NABU) and the Specialized Anti-Corruption Prosecutor's Office (SAPO) – under government control.
The large-scale demonstrations were Ukraine's first major anti-government protests since Russia's 2022 invasion.
When approving the bill last week, Zelensky called it a necessary step to rid the two agencies of 'Russian influence.' Two employees of one of the bodies were arrested last week 'on suspicion of working for Russian special services.'
But on Thursday, the president about-faced, saying in a statement posted to X that he had listened to the Ukrainian people and that the 'right decision' was to reverse the controversial bill.
The law he signed Thursday is a 'guarantee of the proper independent functioning of Ukraine's anti-corruption bodies and all law enforcement agencies,' Zelensky said, adding that the new law will ensure regular polygraph checks for 'all law enforcement personnel who have access to state secrets or have relatives in Russia.'
'This is the right decision. It is very important that the state listens to public opinion. That it hears its citizens. Ukraine is a democracy – without a doubt,' he said.
Ukraine had long been seen as one of the most corrupt countries in Europe. The European Union warned Kyiv that it must implement strong anti-graft measures if it wants to join the bloc.
Ursula von der Leyen, the president of the European Commission, and António Costa, the president of the European Council, both said in identical posts on X that the new law signed Thursday was a 'welcome step.'
'Ukraine's rule of law and anti-corruption reforms should continue. They remain essential for Ukraine's progress on the European path. The EU will continue to support these efforts,' they said.
Kaja Kallas, the EU's High Representative for Foreign Affairs and Security Policy, also wrote on social media that 'Ukraine's move to restore powers of anti-corruption bodies demonstrates its resolve to quickly get back on course when European democratic values are at stake.'
'The rule of law and fighting corruption are crucial for any country aspiring to join the EU,' she said.
Diplomats from the EU countries of the Czech Republic, Estonia, Germany, Latvia, Lithuania, Malta, the Netherlands, Portugal and Sweden also welcomed the move.
CNN's Ivana Kottasová contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
New US-EU trade deal on tariffs ends pharma's geopolitical immunity
For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU. On 27 July, the US government announced a 15% tariff on branded pharmaceutical products imported from the EU. Despite the decrease from the original 30% tariff on pharmaceuticals earlier in the year, this disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public health. The 15% tariff is not expected to happen immediately as implementation will be dependent on a National Security investigation regarding pharmaceutical imports. This trade deal puts the pharmaceutical industry at risk of losing between $13bn and $19bn, with consequences that extend beyond short-term financials. It will force pharmaceutical companies to make a tradeoff between tightening their profit margins and increasing drug prices, with both paths posing a risk to patient access and payer relations. The imposition of tariffs threatens to elevate costs across the pharmaceutical value chain, and could lead to a substantial increase in drug development costs, manufacturing, and distribution, with global supply chains for active pharmaceutical ingredients (APIs), raw materials, and equipment directly exposed. This disruption could create uncertainty in launch planning, particularly for late-stage assets with EU-based manufacturing and production planned for US entry. Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost-effectiveness due to the tariffs. Research and development budgets are already under pressure, and may be further strained as pharmaceutical companies may have to divert budget to firefight the impact of the tariffs. This could hinder innovation and pipeline investment, reducing the much-needed pace of therapeutic innovation across the industry. Earlier in the year, the US administration did signal tariffs for pharmaceutical imports could become a real possibility; this was met with proactive US investment from leading pharmaceutical companies to onshore manufacturing in the US to reduce exposure. Most recently, in July 2025, Biogen announced a $2bn investment into North Carolina, strengthening its US manufacturing position. Other pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Eli Lilly have also increased their investment in US manufacturing, with investments of $55bn, $50bn, and $27bn, respectively. Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns about the potential of tariffs increasing past 15% in the future. A once-shielded sector is facing a geopolitical shift, leaving the pharmaceutical industry vulnerable to global volatility. "New US-EU trade deal on tariffs ends pharma's geopolitical immunity" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
NBC News
19 minutes ago
- NBC News
Russia's Medvedev warns enemies of 'new reality' as Kremlin ditches nuclear treaty
Former Russian leader Dmitry Medvedev has warned that the country's rivals now faced a 'new reality' as the Kremlin formally announced it was no longer bound by a treaty limiting the use of short and medium-range nuclear missiles. Medvedev, who today serves as the deputy chairman of the country's Security Council and is known for issuing frequent apocalyptic threats on social media, was continuing a war of words that prompted President Donald Trump to redeploy two nuclear submarines last week. His latest warning came after the Russian Foreign Ministry announced it would no longer abide by the Intermediate Nuclear Forces Treaty, or INF, an agreement banning Washington and Moscow from deploying ground-based missiles with ranges between 500 to 5,500 kilometers (311 to 3,418 miles). It also comes days before the expiration of Trump's deadline ultimatum for Russia to agree to a ceasefire or face additional tariffs. The INF was already obsolete, with the United States accusing Russia of violating the pact for decades and i tself withdrawing from the agreement in 2019, and Russia has made little secret of its use of these missiles during its war with Ukraine. On Monday the Russian Foreign Ministry said it was formally abandoning any 'efforts to maintain restraint in this area' because the U.S. was moving to deploy similarly ranged weapons systems to Europe and Asia. Russia 'no longer considers itself bound by the corresponding previously adopted self-restrictions,' it said. Medvedev said the withdrawal from the INF was 'the result of NATO countries' anti-Russian policy' — a reference to Moscow's longstanding claim that the Western military alliance is aggressively encircling Russia. 'This is a new reality all our opponents will have to reckon with. Expect further steps.' NBC News has contacted NATO for comment on his remarks. Last week the former Russian leader became involved in a social media spat with Trump. While in Scotland, Trump reduced his initial 50-day deadline for Russia to cease fighting, instead giving it 10-12 days. Medvedev responded by saying that 'each new ultimatum is a threat and a step towards war' between Russia and the U.S. On Friday Trump reacted by ordering two nuclear submarines to be deployed to 'appropriate regions, just in case these foolish and inflammatory statements are more than just that.' This social media back-and-forth is playing out as Russia makes slow, grinding gains on the battlefield in eastern Ukraine. From the skies, Ukrainian civilians endured another hellish night of Russian drone and missile attacks, as well as shelling on the Zaporizhzhia, Kharkiv, Sumy, Kherson and Donetsk regions. Over the past 24 hours at least 15 civilians were killed, officials said. Ukrainian President Volodymyr Zelenskyy thanked Trump for putting pressure on the Kremlin. 'Russia is dragging out the war against Ukraine for one reason only — it has the money to keep the war going,' he said in his nightly address Monday. 'All sanctions that restrict Russia help bring peace. All weapons that strengthen Ukraine help bring peace. All political actions that isolate Russia help bring peace.' Vocing an opinion common among Western experts on Russia, Mark Galeotti, warned against reading too much into comments by Medvedev. 'Medvedev is a professional troll these days. Trying to dig too much meaning into his various iterations is a fool's errand,' said Galeotti, the British-based director of the consultancy Mayak Intelligence. 'Indeed, sometimes I wonder if his statements are precisely intended to tie us into knots as we try to interpret them!'
CNBC
19 minutes ago
- CNBC
5 things to know before the Tuesday open: Palantir earnings Trump applauds American Eagle
Investors who might have had anxiety checking their holdings over the weekend got a nice reprieve on Monday. Stocks rallied to start the new week, with the S&P 500 snapping its four-day losing streak and the Dow Jones Industrial Average erasing its Friday sell-off. All three major indexes ended Monday's session more than 1% higher. Stock futures are slightly higher on Tuesday morning. Follow live market updates here. Tariff news continues to make headlines as market participants count down to Thursday — the most recent deadline set by the White House for it to start collecting tariffs from some trading partners. President Donald Trump said Monday that he would "substantially" hike tariffs on goods coming from India because the country buys Russian oil. The European Union also announced Monday that it would delay enacting planned tariffs on the U.S. for six months. Trump will join CNBC's "Squawk Box" for an interview at 8 a.m. ET Tuesday morning. Stream CNBC live here. Palantir, the buzzy and mysterious defense technology stock, recorded quarterly revenue of $1 billion for the first time. It's an important milestone for the company, which has seen its shares skyrocket and become a favorite of retailer investors given its futuristic focus and eccentric CEO, Alex Karp. As CNBC's Samantha Subin notes, the Denver-based company has become a beneficiary of Trump's governmental cost-cutting initiatives, with its U.S. government revenues jumping 53% year-over-year. Palantir shares popped in extended trading following its earnings report. This week, OpenAI's ChatGPT products are poised to reach 700 million weekly active users. There's a few ways to show just how much that number has ballooned with artificial intelligence's move into the mainstream. First, it's up about 40% from March alone. Even more eye-popping, the number has grown more than fourfold from a year ago. ChatGPT's number of paid business users is also accelerating, up to five million from three million in June. After getting caught in controversy over its new advertising campaign starring actress Sydney Sweeney, American Eagle got a vote of confidence from the White House on Monday. Trump called the campaign the "'HOTTEST' ad out there" in a social media post. He also said that Sweeney, who's known for roles in "Euphoria" and "The White Lotus," is a registered Republican. American Eagle's shares surged more than 23% following the president's post, marking the Pittsburgh-based company's best day in about a quarter of a century. —
